Prostate disorder
MONDO:0003105A disease involving the prostate gland.
Also known as: disease of prostate gland, disease or disorder of prostate gland, disorder of prostate gland, prostate disease, prostate disorder, prostate gland disease, prostate gland disease or disorder
2448 clinical trials for this condition and its sub-types, 16 tagged with Prostate disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate disorder
-
Prostate neoplasm 126 trials · 2,233 incl. sub-types
5 sub-types
- Prostate cancer 1,921 trials · 2,225 incl. sub-types Sub-types →
- Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types Sub-types →
- Prostate intraepithelial neoplasia 2 trials Sub-types →
- Benign neoplasm of prostate 0 trials Sub-types →
- Prostate phyllodes tumor 0 trials Sub-types →
-
Benign prostatic hyperplasia 226 trials
-
Prostatitis 4 trials · 15 incl. sub-types
5 sub-types
- Chronic prostatitis 14 trials
- Trichomonas prostatitis 0 trials
- Gonococcal prostatitis 0 trials Sub-types →
- Granulomatous prostatitis 0 trials
- Prostatocystitis 0 trials
-
Prostate calculus 0 trials
-
Prostatic cyst 0 trials
Most studied deeper sub-types
-
New hope for tough prostate cancer: first human trial of VIR-5500 begins
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…
Phase 1/2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Phase 1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests a new radioactive drug (lutetium rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or lower PSA levels. About 82 …
Phase 1/2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the comb…
Phase 1/2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can MRI predict finasteride failure? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand why some men with an enlarged prostate (BPH) do not respond to the common drug finasteride. Researchers will follow 120 men starting finasteride, tracking their symptoms and using MRI scans and genetic tests over three years. The goal is to find ways…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC